A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Name: A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Creator: Vivli
Published: 2025-12-16 15:15:39
License: 暂无描述

DataCite Commons2025-12-16 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00012369/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.

提供机构：

Vivli

创建时间：

2025-12-16